Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Johnson and Johnson

Generated: October 20, 2017

DrugPatentWatch Database Preview

MEN'S ROGAINE Drug Profile

« Back to Dashboard

What is the patent landscape for Men's Rogaine, and what generic Men's Rogaine alternatives are available?

Men's Rogaine is a drug marketed by Johnson And Johnson and is included in one NDA. There is one patent protecting this drug.

This drug has eighteen patent family members in eleven countries.

The generic ingredient in MEN'S ROGAINE is minoxidil. There are eight drug master file entries for this compound. Fifty-seven suppliers are listed for this compound. Additional details are available on the minoxidil profile page.

Summary for Tradename: MEN'S ROGAINE

US Patents:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list87
Clinical Trials: see list2,509
Patent Applications: see list4,334
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MEN'S ROGAINE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Johnson And Johnson
AEROSOL, FOAM;TOPICAL021812-001Jan 20, 2006OTCYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MEN'S ROGAINE

Country Document Number Estimated Expiration
European Patent Office1695708► Subscribe
European Patent Office1073439► Subscribe
Canada2328950► Subscribe
Austria331517► Subscribe
AustraliaPP310798► Subscribe
Germany69932158► Subscribe
Japan2002512192► Subscribe
Portugal1073439► Subscribe
Japan4338455► Subscribe
Spain2268856► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus